
Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.
In SURPASS-CVOT, Mounjaro achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE-3), including cardiovascular death, heart attack, or stroke, versus Trulicity.